Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Market Cap | 127.74M |
| Revenue (ttm) | 2.67M |
| Net Income (ttm) | -76.71M |
| Shares Out | 116.36M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 531,758 |
| Open | 1.02 |
| Previous Close | 1.02 |
| Day's Range | 1.01 - 1.03 |
| 52-Week Range | 0.91 - 4.00 |
| Beta | 1.94 |
| Analysts | Hold |
| Price Target | 2.05 (+101.0%) |
| Est. Earnings Date | Nov 8, 2021 |
About CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for...
Financial Performance
In 2020, CRBP's revenue was $3.94 million, a decrease of -89.11% compared to the previous year's $36.14 million. Losses were -$111.27 million, 55.7% more than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CRBP stock is "Hold." The 12-month stock price forecast is 2.05, which is an increase of 100.98% from the latest price.
News
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Corbus Pharmaceuticals Q2 Earnings
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 71.15% year over year to ($0.15)...
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided corporate updates and reported fina...
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist
Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informat...
Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomy...
Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflamm...
3 Biotech Stocks With Big Catalysts in June
Important events on the horizon could push these biotech stocks higher or press them further into the dirt.
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
PSY: 14 Things to Know About the First Psychedelic Stocks ETF in the U.S.
PSY (PSY) is getting extra attention on Monday as investors seek out new investments in the psychedelic medical market today. The post PSY: 14 Things to Know About the First Psychedelic Stocks ETF in th...
This Biotech Penny Stock Is Better Than Dogecoin
You might want to avoid buying it, though.
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
Norwood, MA, June 01, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced licensing deals for two new monoclonal antibodies (mAbs),...
3 Biotech Penny Stocks That Are Popular on Reddit Right Now
Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News a...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici...
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals H o ldings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...
Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Here Are the Cannabis Stocks That Caught Fire This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Recap: Corbus Pharmaceuticals Q1 Earnings
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 67.44% year over year to ($0.14), which beat the estim...
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
Norwood, MA, May 13, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici...
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici...
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4/20 Holiday Week Had These Cannabis Stocks Fired Up
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment o...
Norwood, MA, April 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...
The Week Where New York Legalizes Recreational Marijuana
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyo...
Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...